Lumos Diagnostics has announced further progress in the U.S. commercialisation of FebriDx® across its priority top-100 urgent care target list.
Commercial highlights
- 215 live FebriDx® sites, up from 170 in July
- 405 sites under evaluation, up from 350
- Two new top-100 urgent care groups have progressed to adoption across more than 40 sites combined
- Two further top-100 urgent care groups are undertaking clinical and economic validation across more than 45 sites combined
These four accounts are in the top-100 urgent care groups and reflect continued progress through Lumos’s commercial pathway: validate clinical utility, workflow fit and economics, then expand through network rollout.
Lumos Diagnostics CEO, Doug Ward:
“This is the same pilot-to-validation-to-expansion approach demonstrated at WellStreet Urgent Care, where FebriDx® expanded to 44 live sites following its initial pilot.
“The repeatability of this model provides us with a strong foundation for scaling our top 100 urgent care strategy with confidence.”
This webpage is a summary only and should be read together with the full ASX announcement. The announcement includes forward-looking statements that are subject to risks, uncertainties and assumptions. Forward-looking statements are not guarantees of future performance. All FebriDx® sales in the United States are made through Lumos’s exclusive distribution partner, Phase Scientific, and Lumos recognises revenue when product is shipped from Lumos to Phase Scientific.
